Introduction: Mutation of the HBV precore gene prevents the production of HBeAg, which is an important target for immune responses. Distribution of this mutation varies along with frequency of HBV genotypes in accordance with geographic and ethnic variations. The general objective of this study was to evaluate the prevalence and characteristics of precore mutation in Iran and its correlation with genotypes of hepatitis B. Methods: In this cross-sectional study, viral DNA of 182 Iranian hepatitis B surface antigen positive patients who were admitted to Bandar Abbas Blood Transfusion Organization in 2012 and 2013 was retrieved from their serum samples. HBeAg, anti-HBe, and anti-HBc IgM diagnostic tests were performed using ELISA kits. Precore and Pre-S regions were amplified using specific primers and PCR thereafter to determine the genotypes; precore mutation, PCR, and restriction fragment length polymorphism (RFLP) methods also were applied. SPSS version 12 was used for data analysis by Mann-Whitney U test, Fisher's exact probability test, and t-test. Results: A total of 62 patients (34.1%) had precore mutation (A1896G), and genotype D was the predominant genotype in these patients, which was followed by an unknown genotype that was suspected for genotype B. Interestingly, the relationships between precore mutation and HBeAg (p=0.037) and genotype D (p=0.005) were significant; however, no correlation was observed between this mutation and acute or chronic hepatitis and sex of patients. Conclusion: This study found high prevalence of precore mutations in southern Iran, which was significantly associated with HBeAg and genotype D.
Introduction
Hepatitis B virus (HBV) is a blood-borne hepatotrophic virus that is the most widely recognized reason for genuine liver disease on the planet. More than 350 million individuals are infected with HBV around the world (1, 2). A few studies have additionally recommended that the hereditary attributes of HBV, including HBV genotype and particular hereditary mutations, are connected with the advancement of genuine liver disease (3-6). The majority of respective mutations mainly occur in precore and core regions in the gen C of HBV. The precore protein encoded by the precore region is further processed in the endoplasmic reticulum to produce secreted HBeAg. The most naturally occurring mutation in the HBV precore gene is substitution of a guanine (G) to adenine (A) at position 1896. The G1896A precore mutation leads to a conversion of codon 28 from TGG (tryptophan) to a premature stop codon TAG. Accordingly, the translation of the precore protein is prevented, and HBeAg production is completely abolished (7-11). The HBe antigen is targeted by immune responses (both cellular and humoral), which leads to disappearing of e antigen. Precore mutations help viruses to avoid detection by the host immune system (12). Single substations and frameshifts in the HBV precore region were infrequent and unclear, as the clinical relationship was demonstrated (13, 14) . The prevalence of the precore mutation varies from 20% to 95% and more commonly observed in HBeAg-negative patients (15). HBV genetic is variable both as the emergence of mutations in each infected subject and the evolution of genotypes (16). A genetic classification has defined eight genomic groups, genotypes A to H (17-22). Each HBV genomic group indicate a distinct geographic and ethnic distributions, which have been related to special subsequent complications ranging from mild mental disorders to health-threatening conditions (23-28). Genotype A has a worldwide distribution and is the most common genotype in nonMediterranean Europe, India, North America, and sub-Saharan Africa. Genotypes B and C are found primarily in Australia and East and Southeast Asia (29). More than half of the HBV carriers are estimated to live in these areas (30). Genotype D is more common in the Middle East and Mediterranean area, and genotype E is more commonly detected in West Africa (25, 29, 31). Genotype F has been reported from Native Americans (25). Genotype G is reported in samples from USA, France, and Mexico (17). Also genotype H is reported from Central and South America (18). There is an association between mutations in the precore region of the HBV and HBV genotype, so the prevalence of infection with G1896A precore mutant is related to HBV genotypes in different geographic areas. Its prevalence is high in the Far East and Mediterranean regions and low in northern Europe and United States (32). However, controversy exists regarding the correlation between hepatitis B genotypes and precore mutation. Although some studies have shown that precore mutation is related with HBV genotypes, the exact kind of relations varied among these studies and remains unclear. G1896A mutation is most commonly associated with genotypes D, E, and B of HBV and is rare in other genotypes of HBV. (16, (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) . The importance of screening for precore mutation is mainly comprehensible in blood transfusion centers because the transmission of HbeAg negative viruses (precore variants) can lead to severe complications, especially in immunosuppressed or immunocompromised patients who need blood products (43) . In addition, there is a lack of studies about the spread of HBV genotypes and precore mutations in Iran, especially in Bandar Abbas City in southern Iran, which is one of the main communication ports of Iran with the Persian Gulf countries. This connection can distinguish various characteristics of this region from other parts of the country (44) (45) (46) . Thus, the present study was conducted with the aim of determining prevalence and characteristics of precore mutation and its correlation with genotypes of hepatitis B in the blood transfusion center of Bandar Abbas, Iran.
Materials and methods

Patient series
In this cross-sectional survey, serum samples were obtained from 182 HBsAg positive patients, which were composed of 144 (79.12%) males and 38 (20.88%) females who were admitted to Bandar Abbas Blood Transfusion Organization in 2012 and 2013. The samples were stored at -20°C. No patient had a positive test for human immunodeficiency virus and hepatitis C and D virus. Patients were excluded if they had received antiviral therapy or had HBV recurrence after liver transplantation.
Serologic markers
HBe Ag and Ab and anti-HBc IgM were measured using ELISA and DIAPRO kits (Italy). HBe Ag and Ab tests are indicative of viral replication. Further, the anti-HBc IgM is used for detection of chronicity of the disease.
HBV-DNA extraction and HBV genotyping
A Roche High Pure Viral Nucleic Acid kit (Roche Molecular Biochemicals, Germany) was used for DNA extraction. Restriction fragment length polymorphism (RFLP) was used for determination of HBV genotypes as described by Lindh et al. (47) . The pres-S region was amplified and digested by AvaII and MboI restriction enzymes. In short, primers GenoP1 (sense, nt 2823-2845, 5'-TCACCATATTCTTGGGAACAAGA-3') and GenoP2 (Antisense, nt 80-61, 5' TTCCTGAACTGGAGCCACCA-3') were used in PCR to amplify the fragment encompassing nucleotide 80 to 2823, including 479 nucleotides, which contain PRE-S region. 5 μL of the resuspended DNA were added to an amplification mixture containing 5 μL of 10× Taq polymerase buffer, 2μL of 50 mmol/L Mgcl2, 1 μL of 10 mmol/L deoxyribonucleotide triphosphates, 1 μL (5U) of Taq polymerase (Promega, Beijing, China), and 10 pmoL of each primers GenoP1 and GenoP2. The PCR profile was started with 5 min denaturation at 94°C. After that, amplification, annealing, and extension was done. Strand synthesis was completed at 72°C for 7 min. Restriction enzymes including Ava II and MboI (New England Biolabs, Inc., USA) were used for incubation with PCR products. The amplified products were run on 3% agarose gel and visualized under UV. For determination of HBV genotypes, the results were compared with Lindh patterns (47).
Detection of Precore Mutation
We tested the samples for precore stop codon (G1896A). A similar procedure for HBV genotyping was used in this step. Two HBV primers (Pre1 and Pre2) were used in the first PCR amplification. An aliquot of reaction product was then further amplified in a second reaction with primers, Pre2 and Pre3, which are contained within the region spanned by the first two primers. The primer sequences were pre1, 5'-CACCTCTGCCTAATCATCTC-3' (sense, nt 1826-1845); pre2, 5'-CTGACTACTAATTCCCTGGATGCTGGGTCT-3' (antisense, nt 2160-2131); pre3, 5'-CAAGCCTCCAAGCTGTGCCTTGGGTGGCCTT-3' (antisense, nt 1865-1895). The amplification mixture was contained 2.5 μL of 10× Taq polymerase buffer, 0.5 μL of 25 mmol/L deoxyribonucleotide triphosphates, 2.5μL of 50 mmol/L Mgcl2 ,0.4 μL of Taq polymerase (Promega, Beijing, China) and 10 pmoL each of primers Pre1 and Pre2 (total volume of 25 μL). All the procedures of the first-round PCR were similar to those for HBV genotyping. For second-round PCR, 1 μL of the first-round PCR products was used. The condition was the same but with the primers Pre2 and Pre3, with the same procedure. According to Lindh et al., the PCR products were incubated with restriction enzyme Bsu36I that recognize 5'-CCTNAGG-3 sequence and cut C gene into two fragments of 261 and 34 bp in length. Thus, in the absence of PC mutation the production was a fragment of 295 bp in length. The products were visualized by 3% agarose electrophoresis and ethidium bromide staining.
Statistical Analysis
Data analysis was done using SPSS version 12.0 (SPSS Inc., Chicago, Illinois, USA), and a p-value less than 0.05 was considered to be significant. Mann-Whitney U test and Fisher's exact probability test were used for comparing the proportions of each factor between groups, and group means were compared using the t-test.
Results
Demographics and viral characteristics
A total of 182 serums were enrolled in our study. Thirty-eight (20.88%) of patients were female, and 144 (79.12%) were male. Precore (G1896A) mutation was found in 34.1% (62 samples) of the study population, which produced two fragments of 261 and 34 bp in length, which were observable by electrophoresis (Figures 1, 2 ). Three RFLP patterns were identified in relation to HBV genotypes in the present study, two patterns were belonged to genotype D, and one pattern was not matched with any of Lindh patterns (47) . Serological tests showed that 169 samples (92.9%) were HBeAg negative and 13 samples (7.1%) were HBeAg positive. Anti-HBe test also indicated replication of the virus was positive in 159 sample (87.4%) and negative in 23 samples (12.6%). This difference between HBeAg and HBeAb status could be due to a small proportion of patients, which are positive for both of the HBeAg and HBeAb tests, simultaneously. Finally, Anti-HBc IgM were detected in four (2.2%) samples that indicated acute hepatitis in these cases (Table 1) .
Relationship between preC mutant and HBV genotypes
As described, PCR products were incubated with restriction enzymes, the product restriction patterns were compared with Lindh patterns, and genotypes were determined. Three different patterns were found: two patterns were consistent with Lindh patterns and Belonged to genotype D. However, one pattern was not matched with Lindh patterns. All sequences of genotype D in NCBI had a deletion in their Pre-S region, which produced a fragment of 446 bp in length instead of a fragment of 479 bp in length. The first pattern in the current study had no excision site for AvaII. However, it was cut to three fragments by the MboI enzyme (306 nt, 88 nt, 52 nt). This pattern was similar to the D2 pattern, which was obtained by Lindh. The second pattern had a deletion of 183 nucleotides; thus, a 263 nt fragment was amplified, which had no site for AvaII and two sites for MboI (123 nt, 88 nt, 52 nt). This pattern was similar to the Ddel pattern, which was obtained by Lindh. The third pattern, which was not matched with Lindh patterns, was a 446bp amplified fragment that was cut into three fragments by MboI (306 nt, 88 nt, 52 nt). It was excised into two fragments of 300 bp and 146 bp in length by AvaII, which were not matched with any of patterns achieved by Lindh (Figure 3, 4) . However, it seems that this pattern belonged to the B genotype based on a comparison with Lindh patterns. Data analysis indicated a strong correlation between HBV genotype D and precore variants (p=0.005).
Relationship between HBeAg/Ab and Anti-HBc IgM status and preC mutation
Mutations in the precore region were found in 61 samples (36.1%) among 169 HBeAg-negative and one sample (7.7%) among 13 HBeAg-positive patients, respectively. Hbe Ag negative patients had higher prevalence of preC mutation compare with HBe Ag negative patients (36.1% vs. 7.7%, p=0.037). Thus, our findings indicated statistically significant association between HBeAg/Ab status and precore mutation. However, there was no precore mutant among anti-HBc IgM-positive patients, and no statistically significant association was observed (p > 0.05).
Relationship between preC mutation and Gender
The frequency of precore mutation was 49% in male patients and 51% in female patients. Thus, no correlation was found between precore mutation and gender of patients (p > 0.05). , and G, which are matched with a D2 pattern of Lindh patterns that were cut into three fragments of 52nt, 88nt, and 306nt by MboI and had no excision site for AvaII (446bp). Second pattern: Sample F, which is matched with Ddel pattern of Lindh patterns that were cut into three fragments of 52nt, 88nt, and 123nt by MboI and had no excision site for AvaII, which produced a 263bp fragment. The third pattern belonged to samples B, C, and D, which were not matched with any of the Lindh patterns.
Discussion
In this study, we have assessed the relationship between preC mutant and HBV genotypes, HBeAg/Ab status, antiHBc IgM test, and gender of patients. Mutation of G1896A in PreC region shuts off the HBe Ag synthesis by introducing a stop codon, (9, 48). In the present study, precore variants were found in 34 (39) . Two other studies also indicated the G1896A precore mutation was more frequent in the group of patients with genotype D than in the patients with genotype A (38, 49). These findings were in agreement with the theory that the relation between G1896A precore mutation and the HBV genotypes is due to different stabilization energy of each genotype as a result of the base pairing of the stem loop structure of the encapsidation sequence of pregenome RNA. This stabilization is the result of best pairing in the presence of these mutations. The G1896A mutation occurs when nucleotide 1858 is composed of the thymine-nitrogen base, which leads to better stabilization in lower stem. (65) . The frequency of the G1896A mutation was significantly higher in the HBe Ag negative patients in our study, which was compatible with results of previous studies. These results indicate that the appearance of the preC mutation is directly associated with HBe Ag seroconversion, which is in favor of the fact that PreC mutation turns off the synthesis of HBe Ag (29, 35, 54). High prevalence of preC mutation in a later phase of HBV infection is associated with viral replication and hepatic necro-inflammatory activity (12, 32). Wintermeyer et al. also reported that precore variants were more common in anti-HBe positive children, but the difference did not reach statistical significance (66) . However, in another study, Chang MH et al. denied any relationship between anti-HBe status and PC mutation, which suggest at least no strong evidence for the hypothesis that the mutant is selected by host immune pressure (67) . Finally, no correlation was found between precore mutation and gender of patients based on our findings. Although, in a recent study, Pivert et al. indicated that the mutated and mixed preC viruses were more common among males, several studies denied this relationship (68, 69) .
Conclusions
In line with previous scientific evidence, preC variants were more common in patients who were negative for HbeAg in this study. Additional findings of our study were compatible with previous studies, which claimed that Iranian HBV viruses belong to genotype D and indicated significant association of the preC G1896A mutation with this genotype of HBV. In the future studies, it is suggested to determine the distribution of HBV genotypes using more sensitive molecular assays in large multicenter projects. 
